Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;31(4):400-7.

Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism

Suchitra Krishnan-Sarin  1 , Stephanie O'Malley, John H Krystal
Affiliations
Review

Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism

Suchitra Krishnan-Sarin et al. Alcohol Res Health. 2008.

Abstract

Developing pharmacotherapies to treat alcohol dependence and associated health problems traditionally has been based on gaining a better understanding of the neuroscience underlying alcohol-drinking behavior. To date, three medications have been approved for the treatment of alcohol dependence: disulfiram (Antabuse®), naltrexone (Revia®, Vivitrol®, and Naltrel®), and acamprosate (Campral®). However, these medications have modest efficacy, and there is a great need for newer medications that target different neurochemical systems and which could be used either as adjunctive treatments or to treat subpopulations of drinkers. Furthermore, it also is important to improve current treatment options by understanding and incorporating differences in how people with certain genes respond to medication (i.e., pharmacogenetic differences).

PubMed Disclaimer

Figures

Figure
Figure
Medications and their proposed sites of action on the neural pathways that have been shown to mediate alcohol reinforcement. CB1 = cannabi-noid-1, CRF = corticotrophin-releasing factor, GABA = γ-aminobutyric acid, NA = nucleus accumbens, NK1 = neurokinin 1, VTA = ventral tegmental area.
See this image and copyright information in PMC

References

    1. Acheson A, Mahler SV, Chi H, de Wit H. Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology. 2006;186(1):54–63. - PubMed
    1. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism. 2002;37(5):504–508. - PubMed
    1. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922. - PubMed
    1. Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2008b;28(1):5–12. - PubMed
    1. Anton RF, O’Malley SS, Ciraulo DA, et al. COMBINE Study Research Group Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA Journal of the American Medical Association. 2006;295(17):2003–2017. - PubMed

Publication types

MeSH terms

LinkOut - more resources